latozinemab

DRUG3 trials

Sponsors

Alector LLC, Alector Inc.

Conditions

Frontotemporal dementia (FTD)Neurodegenerative Diseases

Phase 3

Continuation Study for Latozinemab

TerminatedNCT06111014

Alector Inc.Neurodegenerative Diseases

Start: 2023-12-08End: 2026-01-07Updated: 2026-01-21

A Continuation Study of Latozinemab in Participants with Neurodegenerative Disease

CompletedCTIS2023-506805-20-01

Alector LLCNeurodegenerative Diseases

Start: 2024-09-25End: 2026-01-05Target: 32Updated: 2025-10-14

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk For or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene

CompletedCTIS2023-506873-36-00

Alector LLCFrontotemporal dementia (FTD)

Start: 2020-06-29End: 2026-01-06Target: 79Updated: 2025-06-10